Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of ruxolitinib for myelofibrosis.

Expert opinion on pharmacotherapy - 1 Jul 2014

Santos Fabio P S, Verstovsek Srdan

Abstract excerpt

INTRODUCTION: The discovery of the activating JAK2 V617F mutation in patients with myelofibrosis (MF) led to the development of JAK2 inhibitors. The first such inhibitor to enter clinical trials was ruxolitinib . This review summarizes preclinical and clinical data of ruxolitinib in MF. AREAS COVERED: A literature search through Medline employing the terms 'ruxolitinib,' 'INCB018424' and 'myelofibrosis' was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Clinical Trials, Phase I as Topic
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nitriles

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Splenomegaly

Share to Thrombocytopenia

Source

Open in PubMed Open full text

Identifiers

PMID: 24856675
DOI: 10.1517/14656566.2014.923404
PMCID: PMC4824286

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of ruxolitinib for myelofibrosis.PMID 24856675Read ↗

Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.Semantic proximity Read ↗

Janus activated kinase inhibition in myelofibrosis.Semantic proximity Read ↗

Practical management of myelofibrosis with ruxolitinib.Semantic proximity Read ↗

Myelofibrosis: an update on current pharmacotherapy and future directions.Semantic proximity Read ↗

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.Semantic proximity Read ↗

How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.Semantic proximity Read ↗

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.Semantic proximity Read ↗

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.Semantic proximity Read ↗

How I treat myelofibrosis.Semantic proximity Read ↗

Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.Semantic proximity Read ↗

[Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.